R1 900,00
Fat Loss, Appetite Control, Improved Insulin Resistance, Body Composition, Energy Increase, Metabolic Performance, Joint Health, Mood Improvement
R1 900,00
90 in stock
GLP-1, GIP and Glucagon (Triple Receptor Agonist Peptide) is a lab-made synthetic peptide engineered to simultaneously activate three key metabolic receptors: GLP-1, GIP, and Glucagon. It represents the cutting-edge evolution of metabolic research compounds – going beyond dual agonists by adding glucagon receptor activation for even greater effects on appetite, energy expenditure, fat burning, and overall body composition. Developed as a once-weekly subcutaneous injection, it is currently one of the most exciting and powerful tools in metabolic and weight-management research.
Think of the GLP-1, GIP and Glucagon triple agonist as the ultimate ‘metabolic command center’ in one molecule. It hits three pathways at once for results that feel truly next-level.
How it works (super simple):
– GLP-1 and GIP receptors powerfully suppress appetite and improve insulin sensitivity.
– Glucagon receptor activation ramps up energy expenditure and fat breakdown while preserving lean muscle.
– The triple synergy creates unmatched calorie burning, hunger control, and metabolic efficiency.
– Unprecedented weight loss – up to 28.7% body weight reduction in 68 weeks at higher research doses (far beyond what dual agonists have shown).
– Rapid fat loss with muscle preservation – targets stubborn fat while helping maintain lean mass and strength.
– Superior metabolic health – better blood sugar control, improved cholesterol, and reduced inflammation markers.
– Energy & performance boost – many researchers report higher daily energy, better workouts, and faster recovery.
– Bonus signals: potential improvements in mobility, joint comfort, and overall vitality.
In short: This triple-action peptide delivers the strongest, most complete metabolic transformation available in research today – making it a standout for serious body-composition and longevity studies.
No official guidelines exist (investigational), so protocols come directly from Phase 3 trials and clinical research use.
Typical dose (once-weekly subcutaneous injection – belly or thigh):
– Start low and titrate: 2.5-5 mg for the first few weeks.
More information available on Supergroup.
– Triple threat – the first peptide to hit three receptors at once, combining the best of GLP-1, GIP, and glucagon for synergy no single or dual agonist can match.
– Record-breaking results – Phase 3 data shows nearly 29% body weight loss – the highest seen in any metabolic research compound to date.
– Energy-burn booster – the added glucagon effect literally turns up your body’s furnace, helping burn more calories even at rest.
– Muscle-friendly – unlike some older compounds, it helps preserve (and in some cases support) lean muscle during major fat loss.
– Once-weekly convenience – designed for easy weekly injections, making it practical for long-term research.
– Beyond weight – emerging data shows real improvements in joint comfort, mobility, and metabolic health markers.
– Future star – with multiple Phase 3 readouts still coming in 2026, this triple agonist is widely considered the most anticipated metabolic peptide in research right now.
The strongest human data comes from the ongoing TRIUMPH Phase 3 program and earlier Phase 2 trials.
1. Lilly TRIUMPH-4 Phase 3 (Dec 2025): Up to 28.7% average weight loss at 68 weeks (12 mg) plus major improvements in knee osteoarthritis pain and function.
2. Jastreboff et al. NEJM (2023, Phase 2): 24.2% weight loss at 48 weeks with the triple agonist; dose-dependent and well-tolerated.
3. NEJM Phase 2 follow-up publications (2023-2025): Marked reductions in body weight and metabolic improvements vs placebo.
4. ClinicalTrialsArena summary (Dec 2025): First successful Phase 3 readout confirmed superior efficacy; additional TRIUMPH trials completing 2026.
5. PMC meta-analysis (2025): Significant body weight and metabolic marker improvements with the triple agonist.
6. Lilly investor updates (20252026): Consistent 2428%+ weight loss across trials; safety profile appropriate for the class.
7. Verywell Health review (Feb 2026): Up to 28.7% loss but notes monitoring for excessive weight loss and GI effects.
8. ClinicalTrials.gov TRIUMPH program (ongoing 2026): Multiple Phase 3 studies for obesity, diabetes, and comorbidities.
9. Swolverine / research summaries (2026): Triple agonist as the most advanced metabolic peptide; unmatched weight-loss data.
10. WADA Prohibited List (2026): All GLP-1, GIP, and glucagon receptor agonists banned in sport.
Takeaway: The latest Phase 3 results show the strongest weight-loss numbers ever recorded for a single research peptide – positioning the GLP-1, GIP and Glucagon triple agonist as a true game-changer.
Gut Healing, IBD Support, Intestinal inflammation Reduction, Skin Health, Wound Repair, Antimicrobial, Immunity, Powerful Systematic Anti-Inflammatory.
R480,00
Powerful Detoxification, Liver Protection, Immunity Enhancer, Anti-Inflammatory, Skin Brightener, Skin Health, Anti-Aging, Cellular Repair, Clear Toxins.
–
R850,00
Neuropathic Pain Relief, Anti-inflammatory effects, Tissue protection, Healing, Fatigue, Quality of Life.
R550,00
Advanced Cognitive Enhancement, Focus, Learning Speed, Memory, Mental Clarity, Neuroprotection & Brain Repair. Mood & Stress Resilience
R550,00
Lean Muscle Growth, Fat Loss, Improved Body Composition and Metabolism, Faster Recovery and Wound Healing, Better Sleep, Anti-Aging, Skin Elasticity, Bone Density, Ligament and Tendon Strength.
R750,00
All products are sold in powder (lyophilized) form and require reconstitution with a suitable diluent for research purposes only. Research supplies (e.g., syringes, bacteriostatic water) are not included and need to be purchased separately. No personal human dosing instructions are provided, only research dosages from clinical studies. We adhere to all local and national (SAHPRA) laws around Research Only Chemical sales. We are not a pharmacy, nor do we promote or provide any advice for human or animal consumption. Please review our terms and conditions carefully before making a purchase on our website.
You must be 21+ and a licensed research professional.
By clicking “I Agree” you confirm that you have read and accepted the Terms and Conditions stated above.
